StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

SUNPHARMA — SUN PHARMACEUTICAL IND L

Price History

Data as of 26 Jun 2026· via fincrux

How SUNPHARMA has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Upper end of its 12-month range88% of range

Trading about 20% above its 12-month low and near recent highs — historically pricier territory for this stock. It sits above its 200-day average, the longer-term trend.

₹1,553 low₹1,906 high
vs 50-day avg
+3.1%
vs 200-day avg
+7.6%
Beginner mode
Plain English, with everything explained

SUNPHARMA

NSE

SUN PHARMACEUTICAL IND L

Healthcare / Pharma

₹1,862.80
0.00%
last close
0%
Quality Score
A mixed pictureBig money steady

SUN PHARMACEUTICAL IND L passes 1 of 3 checks. There's something to like here, but also a few things to be careful about. Read the four checks below before forming a view.

Company size
₹433728.00 Cr
Price tag
145.0×
Money it earns
12.8%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Watch

Borrowing is a little on the higher side. Worth keeping an eye on.

D/E 0.61goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Watch

Profitability is decent but not quite at the level we'd call strong.

ROE 12.8%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Aligned

Professional investors have been holding steady or buying more — a quiet vote of confidence.

FII+DII 36.9%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidia…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What SUNPHARMA owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings5,0747,79111,22711,13813,605
Equity Capital240240240240240
Reserves24,34823,50823,45424,10022,131
Total Assets40,76540,98741,06543,27343,060
Total Liabilities40,76540,98741,06543,27343,060

Borrowings rising

Total borrowings are up about 168% over the last 5 years — worth watching alongside how much it earns.

Periodic Performance

Yearly net profit for SUNPHARMA — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

After one or more loss-making years, the most recent year is back in profit. That's a pattern in the data, not a forecast.

−₹100 Cr
₹1,691 Cr
₹2,858 Cr
₹4,283 Cr
₹2,623 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹15,586 Crrev ₹20,812 Crrev ₹20,275 Crrev ₹23,003 Crrev ₹20,755 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about SUNPHARMA — observations, not recommendations.

Strengths

2
  • Large professional investors have been holding steady or adding to their stake.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

1
  • Sits near the top of its 12-month range — historically pricier territory for this stock.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
15.9%-1.3 pp
DII· Domestic institutions
21.0%+1.6 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
View the full sector